Showing results (531-540 of 1,988) with videos related to

Sort By:
Pageof 199
Prostate Cancer and Prostatic Diseases|June 10, 2022
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness studyYeva Sahakyan, Aysegul Erman, Naeem Bhojani, et al.
Prostate Cancer and Prostatic Diseases|June 10, 2021
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancerNieves Martinez Chanza, Brandon Bernard, Philippe Barthelemy, et al.
Prostate Cancer and Prostatic Diseases|June 10, 2021
Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline functionDaniel D Joyce, Christopher J D Wallis, Amy N Luckenbaugh, et al.
Prostate Cancer and Prostatic Diseases|January 9, 2021
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusionsZachary R Chalmers, Michael C Burns, Ericka M Ebot, et al.
Prostate Cancer and Prostatic Diseases|June 7, 2017
The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimensD M Moreira, D M de O Freitas, J C Nickel, et al.
Prostate Cancer and Prostatic Diseases|June 21, 2017
Contemporary management of men with high-risk localized prostate cancer in the United StatesA B Weiner, R S Matulewicz, E M Schaeffer, et al.
Prostate Cancer and Prostatic Diseases|October 26, 2021
Comparison of Retzius-sparing and conventional robot-assisted laparoscopic radical prostatectomy regarding continence and sexual function: an updated meta-analysisJunyan Liu, Jindong Zhang, Zongke Yang, et al.
Prostate Cancer and Prostatic Diseases|February 11, 2022
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED RegistryXiao X Wei, Lucia Kwak, Anis Hamid, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2022
KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progressionJianfeng Xu, Zhuqing Shi, Jun Wei, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2021
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trialDavid F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
Pageof 199